Company / SG&A per Share
Kymera Therapeutics, Inc. SG&A per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$1.05
FY2025
5-year range
$0.18 / $1.15
FY2021-FY2025
Trend
-8.1%
vs FY2024
Sector context
#119 of 210
Health Care
What the data says
At $1.05, Kymera Therapeutics, Inc.'s sg&a per share ranks #92 of 210 in the Health Care sector. Improved from $1.15 to $1.05 over the past 2 years.
Based on SEC 10-K filings.
1.05 in FY2025 with a 5-year CAGR of -24.0%.
Improved from $1.15 to $1.05 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +7.3%
- 5-Year CAGR
- -24.0%
- 10-Year CAGR
- -
Sector benchmark
#92 of 210 in Health CareTop 43% of 210This company $1.05 Sector average $29.50
▼
-96.4% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share decreased 8.1% year-over-year.
- Ranks #119 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2019.
- Lowest sg&a per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.05 | -8.1% |
| FY2024 | $1.14 | -0.3% |
| FY2023 | $1.15 | +34.8% |
| FY2022 | $0.85 | +374.1% |
| FY2021 | $0.18 | -95.7% |
| FY2020 | $4.14 | -12.0% |
| FY2019 | $4.70 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026